News Archive

image54

Kuros ends transformational year

December 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise.


Kuros successfully raised CHF 16.1 million from existing and new investors. (read more)


Octavian was acting as Joint Placement Agent 

image55

Poenina successfully completes its CHF 35 million rights offering

November 2, 2018: Poenina Holding AG (PNHO.SW) today announced the successful completion of its CHF 35 million rights offering to fund the acquisition of the Inretis Group.


Link to Poenina's press release (in German language only)


Octavian was acting as Selling Agent

image56

Octavian Top 5 for Q4 2018

October 1, 2018: Today we publish our 'TOP 5' list for Q4 2018. Subscribers can access the full report on the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}


Link to  'TOP 5' Q4 2018 report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image57

Idorsia successfully completes the offering of new shares and convertible bonds

July 11, 2018: Idorsia Ltd (IDIA.SW) today announced that it has successfully placed  11,912,000 new shares, corresponding to  approximately 10% of Idorsia's currently issued share capital, by way of  an accelerated bookbuilding. Additionally, Idorsia successfully placed  CHF 200 million of senior unsecured convertible bonds due  2024. 


Link to Idorsia's press release


Octavian was acting as Selling Agent

image58

Octavian 'TOP 5' for Q3 2018

July 2, 2018:  Today we publish our 'TOP 5' List for Q3 2018. The full report can be  accessed through the RSRCHX platform via the link below and on our  Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image59

Polyphor prices its IPO at CHF 38 per share and lists on SIX Swiss Exchange

May 15, 2018:  Polyphor Ltd ("Polyphor" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, today set the offer price for its shares in the initial public offering (“IPO”) at CHF 38 per share, at the upper end of the offer price range.  


Link to POLN's press release


Octavian was acting as Selling Agent

image60

Octavian 'TOP 5' for Q2 2018

April 2, 2018: Today we publish our 'TOP 5' List for Q2 2018. The full report can be accessed through the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image61

Addex Sucessfully Raises CHF40 million in Capital Increase

March 29, 2018: Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that the company has successfully completed its capital increase, raising CHF40 million.


Link to ADXN's press release


Octavian was acting as Placement Agent.

image62

OCTAVIAN SEMINAR 2018

January 20, 2018: A big thank you to all of the companies and investors that attended the OCTAVIAN SEMINAR 2018 in Zurich and Flims. 


Please save the date for the next one:

OCTAVIAN SEMINAR 2019

January 17-19, 2019


Now off to the slopes...

image63

Octavian 'TOP 5' for Q1 2018

January 2, 2018: Our 'TOP 5' for Q1 2018 can now be accessed through the RSRCHX platform via the link below and on  our Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image64

Octavian on stage at the inaugural Swiss IPO Day 2017

November 28, 2017: Octavian presents on stage in front of 15 grownup Swiss startup companies at the inaugural Swiss IPO Day 2017. Many thanks to the organizers at Swiss Startup Invest for this unconventional and refreshing event.  

image65

ADC Therapeutics Announces Closing of $200 Million Private Financing

 

October 23, 2017: The Octavian team congratulates ADC Therapeutics (ADCT), an  oncology drug development company that specializes in the development of  proprietary PBD-based Antibody Drug Conjugates targeting major cancers,  to the successful raise of $200 million through a private placement.  Octavian supported ADCT in this private placement with targeted access  to its investor client base resulting in the addition of new quality  investors to ADCT’s shareholder registry.


Link to ADCT's press release

image66

Octavian 'TOP 5' for Q4 2017

 

October 2, 2017: We are delighted to bring you the second installment of our  quarterly 'TOP 5' picks as Team Octavian. The full report  can be a  accessed on the following link:


Link to full report on RSRCHX

image67

Octavian 'TOP 5' for Q3 2017

July 3, 2017: We are delighted to present you with our first 'TOP 5' List for Q3 2017 under the Octavian name. The full report can be accessed through the RSRCHX platform via the link below.


Link to report on RSRCHX